Humalog Mix75/25insulin lispro

According to the FDA label: ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

130,368 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Humalog Mix75/25 in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Humalog Mix75/25 adverse event reports by reporter sex
SexReports
Female70,142
Male54,371
Unknown107

By Age Group

View age group data as a table
Humalog Mix75/25 adverse event reports by reporter age group
Age groupReports
0-172,601
18-344,294
35-498,011
50-6421,534
65-7418,560
75+13,425

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Humalog Mix75/25. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Humalog Mix75/25 adverse event reports by reported outcome
OutcomeReports
Non-Serious69,139
Other Serious36,837
Hospitalization33,039
Death5,797
Life-Threatening3,143
Disability2,778

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Humalog Mix75/25. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Humalog Mix75/25 adverse event reports by year
YearReports
20041,188
20051,273
20061,694
20071,565
20081,471
20091,807
20101,861
20112,034
20122,135
20131,766
20144,652
201528,028
20169,274
20178,863
20189,202
20199,213
20209,343
20217,810
20226,737
20235,890
20245,460
20257,802
2026 (partial)1,300

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Humalog Mix75/25

In FDA adverse event reports that mention Humalog Mix75/25, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026